{"preliminary_commentary":{"by_channel":{"x_thread":33},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05888402\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"InTRist","nct_id":"NCT05888402","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=intrist-nct05888402. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"InTRist","arms":[{"description":"Participants will receive 2 cycles of induction therapy of platinum-based chemotherapy combined with Toripalimab, followed by platinum-based concurrent chemoradiation. Then participants will receive Toripalimab consolidation therapy after chemoradiotherapy with maximum 1 years or until disease progression or intolerable toxicity.","label":"Induction Toripalimab and chemotherapy followed by concurrent chemoradiotherapy","type":"EXPERIMENTAL"},{"description":"Participants will receive 2 cycles of induction platinum-based chemotherapy, followed by platinum-based concurrent chemoradiation. Then participants will receive Toripalimab consolidation therapy after chemoradiotherapy with maximum 1 years or until disease progression or intolerable toxicity.","label":"Induction chemotherapy followed by concurrent chemoradiotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Shanghai Junshi Bioscience Co., Ltd."],"completion_date":{"date":"2026-03-20","type":"ESTIMATED"},"conditions":["Local Advanced Non-small Cell Lung Cancer"],"enrollment":{"count":50,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Toripalimab","otherNames":["Tuo Yi"],"type":"DRUG"},{"name":"Concurrent chemoradiation therapy and consolidation immunotherapy","otherNames":["The PACIFIC regimen"],"type":"RADIATION"}],"last_update":"2026-02-27","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","official_title":"The Efficacy and Safety of Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume (Bulky) Local Advanced Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-10-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From date of recruitment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months."}],"references":[{"citation":"Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z, Bi N. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023.","pmid":"38288117","type":"DERIVED"}],"start_date":{"date":"2023-01-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC","url":"https://clinicaltrials.gov/study/NCT05888402"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/intrist-nct05888402"}